



# ARA-290

a synthetic peptide derived from the erythropoietin (EPO) molecule

## Dosage Recommendations

Weekly

5Days/Week

Daily

### Subcutaneous Injection:

#### General Dose:

2 mg per day.

#### Administration Frequency:

Once daily.

#### Treatment Duration:

Commonly administered for 28 days, followed by a monitoring period without treatment to assess lasting effects.

### Intravenous Administration:

#### General Dose:

2 mg per dose.

#### Administration Frequency:

Three times weekly.

#### Treatment Duration:

Typically over a 4-week period.

#### Important Notes:

Condition-Specific Dosing: Dosage may vary depending on the specific condition being treated, such as sarcoidosis-associated neuropathic pain or diabetic neuropathy

MG	BAC Water/ML	Dosage (mg)	Insulin Needle Units	Total Doses Per Vial
16	2	2	25	8

### Useful Information

**Class:** Tissue-protective erythropoietin-derived peptide (Innate Repair Receptor agonist)

#### Mechanism of Action:

ARA-290 is an 8-amino-acid peptide derived from the B-helix region of erythropoietin (EPO), engineered to retain the tissue-protective effects of EPO without stimulating red-blood-cell production.

It selectively activates the Innate Repair Receptor (IRR)—a heterodimer composed of EPOR and CD131—triggering anti-inflammatory, anti-apoptotic, and neuroprotective pathways.

Through this mechanism, ARA-290 helps modulate immune overactivation, protect endothelial cells, and promote small-fiber nerve regeneration, making it valuable for conditions involving neuropathy, ischemia, and microvascular dysfunction.